Sean Freeman - NuVasive Sr Devel
Insider
Sean Freeman is Sr Devel of NuVasive
| Phone | 858 909 1800 |
| Web | https://www.nuvasive.com |
NuVasive Management Efficiency
The company has return on total asset (ROA) of 0.0242 % which means that it generated a profit of $0.0242 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0331 %, meaning that it created $0.0331 on every $100 dollars invested by stockholders. NuVasive's management efficiency ratios could be used to measure how well NuVasive manages its routine affairs as well as how well it operates its assets and liabilities.NuVasive currently holds 1.01 B in liabilities with Debt to Equity (D/E) ratio of 1.22, which is about average as compared to similar companies. NuVasive has a current ratio of 1.15, suggesting that it may not be capable to disburse its financial obligations when due. Note, when we think about NuVasive's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Ehab Esmail | Orthofix Medical | 53 | |
| Mark Quick | Orthofix Medical | N/A | |
| Sri Radhakrishnan | Pulmonx Corp | N/A | |
| BA Chemistry | Orthofix Medical | 63 | |
| Michael Carter | Nevro Corp | 52 | |
| Michael Hutchinson | LivaNova PLC | 54 | |
| David Haffner | Glaukos Corp | N/A | |
| Jason Edie | Paragon 28 | N/A | |
| Brendan Shook | Paragon 28 | N/A | |
| Erik Mickelson | Paragon 28 | 42 | |
| Meghan Scanlon | Paragon 28 | 48 | |
| Krissy Wright | Paragon 28 | N/A | |
| Lisa Paul | Pulmonx Corp | 61 | |
| Geoffrey Rose | Pulmonx Corp | 51 | |
| Richard Carter | Nevro Corp | 53 | |
| John McKune | Pulmonx Corp | 49 | |
| Collin DSilva | Bruker | 67 | |
| Alex Shvartsburg | LivaNova PLC | 54 | |
| S Mansbach | Avanos Medical | N/A | |
| David Crawford | Avanos Medical | N/A | |
| Joseph Powers | Si Bone | 64 | |
Management Performance
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 |
NuVasive Leadership Team
Elected by the shareholders, the NuVasive's board of directors comprises two types of representatives: NuVasive inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NuVasive. The board's role is to monitor NuVasive's management team and ensure that shareholders' interests are well served. NuVasive's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NuVasive's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliet Cunningham, VP Relations | ||
| Sean Freeman, Sr Devel | ||
| Michael Farrington, VP Culture | ||
| Nathaniel Esq, Gen VP | ||
| Dale Wolf, VP Operations | ||
| Ryan Donahoe, VP Officer | ||
| Matthew Harbaugh, Ex CFO | ||
| Johnson Lai, Chief Officer | ||
| Marc Rosenbaum, Co VP | ||
| Christopher Barry, CEO, Director |
NuVasive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NuVasive a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 2.91 B | |||
| Shares Outstanding | 52.45 M | |||
| Shares Owned By Insiders | 0.27 % | |||
| Shares Owned By Institutions | 99.73 % | |||
| Number Of Shares Shorted | 5.76 M | |||
| Price To Earning | 51.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Other Consideration for investing in NuVasive Stock
If you are still planning to invest in NuVasive check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NuVasive's history and understand the potential risks before investing.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |